G
Gary T. Ferguson
Researcher at Wayne State University
Publications - 202
Citations - 11594
Gary T. Ferguson is an academic researcher from Wayne State University. The author has contributed to research in topics: COPD & Olodaterol. The author has an hindex of 38, co-authored 194 publications receiving 10341 citations. Previous affiliations of Gary T. Ferguson include University of North Carolina at Chapel Hill & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study
Bartolome R. Celli,Nicola E. Thomas,Julie A. Anderson,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Jørgen Vestbo,Katharine Knobil,Julie C. Yates,Peter M.A. Calverley +9 more
TL;DR: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.
Journal ArticleDOI
Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program.
TL;DR: In this article, a consensus statement recommends the widespread use of office spirometry by primary-care providers for patients ≥ 45 years old who smoke cigarettes, accompanied by strong advice to quit smoking and referral to local smoking cessation resources.
Journal ArticleDOI
Adherence to inhaled therapy, mortality, and hospital admission in COPD
Jørgen Vestbo,Julie A. Anderson,Peter M.A. Calverley,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Katharine Knobil,Lisa R. Willits,Julie C. Yates,Paul W. Jones +9 more
TL;DR: Adherence to inhaled medication is significantly associated with reduced risk of death and admission to hospital due to exacerbations in COPD and was even stronger when analysing on-treatment deaths only.
Journal ArticleDOI
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Courtney Crim,Peter M.A. Calverley,Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Lisa R. Willits,Julie C. Yates,Jørgen Vestbo +9 more
TL;DR: Despite the benefits of ICS-containing regimens in COPD management, healthcare providers should remain vigilant regarding the possible development of pneumonia as a complication in patients receiving such therapies.